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Leukemia inhibitory factor (LIF) is a multifunctional cytokine important in nerve and muscle
cells development and maintenance. The effects of LIF on the formation of neuromuscular
junction (NMJ) have not been studied directly, that is why we employed the in vitro model of
human muscle cell cultures innervated by rat embryonic motor neurons. In this model, several
aspects of neuromuscular junction formation can be studied. The aim of the study was to test if LIF
promotes the formation of functional NMJ. The effects of LIF on neuronal outgrowth, acetyl-
choline receptor accumulation and the formation of functional contacts were tested. Co-cultures
treated with higher concentrations of LIF have increased neuronal outgrowth, higher number of
acetylcholine receptor clusters and finally at later stages also a higher degree of functional in-
nervation. LIF positively promotes the formation of neuromuscular junction in specific con-
centration range. Effects appeared to be stronger at later stages of NMJ formation in our co-cul-
tures. The model of in vitro innervated human muscle cell can be a useful experimental system
for testing toxic and therapeutic effects of substances on the formation and development of












Neurotrophic factors play a profound role in the develop-
ment, maintenance and regeneration of the nervous sys-
tem. Further more they are involved in the formation and
maturation of neuromuscular junction, where appropriate
trophic interactions between motor neurons and muscle
are very important for successful formation of functional
neuromuscular system.1-3 Neurocytokine family of neuro-
trophic factors includes ciliary neurotrophic factor (CNTF)
and leukemia inhibitory factor (LIF).4 LIF is synthesized
in great variety of cell types and as well as in motor neu-
rons and skeletal muscle.5,6 Intracellular actions of LIF
are mediated via transmembrane receptor complex
(LIFR) activation.7 Expression and synthesis of LIF and
its receptor in motor neurons, skeletal muscle and other
tissue is precisely regulated depending on the develop-
mental and physiological situation.8 LIF is ubiquitous mul-
tifunctional cytokine 9,6 and unique in its independent neu-
rotrophic and myotrophic actions.10 Neurotrophic effects
of LIF promote survival of embryonic motor neurons in
vitro and it is essential factor in the process of motor
neuron regeneration.11,12 Several studies also support an
active role of LIF in skeletal muscle development and
regeneration. LIF promotes myoblast proliferation and
growth.13 In regenerating skeletal muscle LIF promotes
different aspects of this process as shown in the study by
Kurek et al.,14,15 further it increases the size of regener-
ating muscle fibers16 and it might be essential in func-
tional recovery.17
The role and effects of LIF and other neurotrophic
factors on the formation of neuromuscular junction (NMJ)
are still poorly understood partly due to a lack of appro-
priate experimental models. The experimental model of
in vitro innervated human muscle enables studying more
closely the different aspects of NMJ formation. In this
experimental model human muscle are innervated with
embryonic rat spinal cord motor neurons which results
in the formation of functional and long lived NMJ and
highly mature and contracting myotubes.18-20 In the pre-
sented study, the in vitro model of innervated human
muscle was used in order to find out if LIF promotes the
formation of NMJ.
EXPERIMENTAL
Preparation of Human Muscle Cell and Embryonic
Rat Spinal Cord Co-culture
All studies reported here were approved by the Ethical
Commission at the Ministry of Health of the Republic of
Slovenia (permit No: 63/01/99). Co-cultures were prepared
as described before.18-20 Human myoblast cultures were de-
rivered from muscle pieces routinely discarded at the ortho-
paedic operations on patients that did not suffer from any
muscular disease. Briefly, human muscle tissue was clean-
ed of adhering connective tissue, cut to 0.5–1 mm pieces
and trypsinized to release muscle satellite cells. Cells were
grown to clonal density in 100 mm Petri dishes in Minimum
Essential Medium (MEM; Invitrogen, UK) with 10 % Fetal
Bovine Serum (FBS; Invitrogen, UK) at saturated humidity
in a mixture of 5 % CO2 and air at 37 °C. Myoblast colo-
nies identified by morphology and devoid of fibroblast con-
tamination were trypsinized and further expanded in 75 cm2
flasks containing MEM with 15 % FBS. Confluent myoblast
cultures were harvested by trypsinization prior to myoblast
fusion and were plated on glass coverslips coated with 1:2
mixture of gelatine (1.5 g dissolved in 100 ml of water;
Sigma) and human plasma, in 35 mm six-well plates. Myo-
blasts were grown in F-14 medium (Invitrogen, UK) sup-
plemented with 10 % FBS, 50 ng/ml Fibroblast Growth Fac-
tor (Sigma), 10 ng/ml Epidermal Growth Factor (Sigma) and
10 mg/ml Insulin (Sigma). Timed pregnant Wistar female rats
were sacrificed by CO2 narcosis at 14 days of gestation, as
specified by the Veterinary Administration of the Ministry
for Agriculture, Forestry and Food of Slovenia (permit No:
323-02-74/00) and in accordance with European Communi-
ties Council Directive (86/609/EEC). All efforts were made
to minimize the number of animals used and their suffering.
The embryos were removed by caesarean section and plac-
ed in Earle’s Balanced Salt Solution (Invitrogen, UK). Spi-
nal cords were aseptically dissected from E14 embryos cut
in 1-mm thick cross-sections. For each section, the anatom-
ical connections with dorsal root ganglia and the integrity
of meninges were preserved. Four to five explants were plac-
ed on to a monolayer of fused myoblasts grown on glass
coverslips. After 1 week, co-cultures were grown in F-14
medium containing 5 % of FBS and devoid of FGF and EGF
to promote further differentiation of muscle cells into myo-
tubes. In order to study the effects of LIF we tested five dif-
ferent concentrations of LIF (1, 5, 10, 20 and 50 ng/ml) (R&D
Systems, MN, USA), same concentrations were already test-
ed in long term spinal cord cultures.21
Quantitative Analysis of Functional Innervation
The effects of LIF on neuronal outgrowth were determinat-
ed by counting the neurite roots growing out of spinal cord
explant at various time intervals during the experiment and
as described before.20 The effect of LIF on acetylcholine
receptor (AChR) accumulation was determinated by count-
ing the number of AChR clusters. AChR clusters were vi-
tally labelled by rhodamine-conjugated a-bungarotoxin
(Molecular Probes, OR, USA) for 1 hour at the concentra-
tion of 1 mg/ml diluted in culture medium with 1 % bovine
serum albumine and without serum. Co-cultures were then
washed with F-14 medium without serum and a-bungaro-
toxin three times and fixed in 4 % paraformaldehyde. For
easier identification of myotubes we stained nuclei with
Hoechst 33342 (Molecular Probes, OR, USA) for 5 minutes
at the concentration of 1 mg/ml. Coverslips were mounted
on glass slides with Vectashield. The number of AChR clus-
ters per microscopic field was counted as already perform-
ed in other studies.22 AChR clusters were viewed under fluo-
rescent microscope (Axioscope Zeiss, Germany) with 40x
objective. Between 20 to 40 different randomly chosen mi-
croscopic fields (final magnification of microscopic field was
400x) were examined in the innervation areas20 of the con-
traction-positive explants for each set of control and LIF treat-
ed co-cultures. The efficiency of functional neuromuscular
junction formation was quantitated by determining i) the
number fraction (expressed in percents) of contraction-pos
itive explants, and ii) the number of contracting units within
the innervation areas of individual contraction-positive ex-
plants. The explant was considered contraction-positive if it
exhibited at least one contraction unit in its area of innerva-
tion. The fraction of contraction-positive explants was de-
termined in the population of explants placed on human myo-
tubes at the first day of co-culture. The number of contrac-
tion-positive explants was counted at certain time points dur-
ing the experiment and from this data an average fraction of
contraction-positive explants for each set of co-cultures was
determined. Contracting unit was defined as a distinct group
of muscle fibers contracting simultaneously at a frequency
which was different from the frequencies of contractions of
other contracting units. By counting these units we were
not directly counting the number of NMJs since the number
of fibers belonging to each contracting unit is difficult to
asses. Results are given as mean ± SD. Statistical analysis
was performed using Student t-test, statistical significance
was accepted at P<0.05.
RESULTS
In most of the co-cultures, neurons started to grow out of
spinal cord explants in the first days after establishment
of the co-cultures. Neuronal outgrowth was quantitated
by counting the number of neuronal roots per spinal cord
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explant at various time points. This number was continu-
ously increasing from day 3 (3.25 ± 0.84) to day 17 after
establishment of co-cultures with 6.25 ± 0.81 neuronal
roots per spinal cord in control co-cultures. Later on, the
number of neuronal roots per spinal cord became stabi-
lized at the same level or even slightly but not signifi-
cantly decreased (Figure 1). Similar results were observ-
ed in co-cultures treated with lower concentrations of LIF
(5 and 10 ng/ml). In co-cultures treated with 1 ng/ml of
LIF decreased neuronal outgrowth at all time points af-
ter day 10 was observed. In comparison with control
co-cultures at day 21 neuronal outgrowth reached the
value 4.21 ± 0.69, which is 33 % less than in controls.
Neuronal outgrowth was significantly higher from day 5
in co-cultures treated with higher concentrations of LIF
(20 and 50 ng/ml). At day 21 there was 9.24 ± 0.68 neu-
ronal roots per spinal cord, which is 1.77 times higher
than in control co-cultures at this time point.
Further we investigated the effects of LIF on AChR
clustering by counting the AChR clusters in microscopic
fields in close vicinity of spinal cord explants in 15 days
old co-cultures. For each set of co-cultures treated with
different concentrations of LIF twenty to thirty different
microscopic fields were examined. The average number
of AChR clusters per microscope field in control co-cul-
tures was 7.8 ± 0.8, similar results were obtained in co-cul-
tures treated with lower concentrations of LIF (6.9 ± 1.2
in 1 ng/ml, 7.4 ± 1 in 5 ng/ml and 8.5 ± 0.8 in 10 ng/ml),
Figure 2. The number of AChR clusters was significant-
ly higher in co-cultures treated with 20 ng/ml of LIF
(11.3 ± 1.0) which is 45 % higher and in co-cultures
treated with 50 ng/ml of LIF (10.9 ± 0.9) 39 % higher
than in control co-cultures.
We did not observe any contractions prior to day 7
after the establishment of co-cultures. After that, pro-
gressively more explants became contraction-positive. The
average fraction of contraction-positive explant through
time course of experiment in control co-culture was 40 %
(Figure 3). No statistically significant difference in this
respect could be observed between control co-cultures
and co-cultures treated with 1 ng/ml of LIF, where the
average fraction of contraction-positive explants was 40 %
and co-cultures treated with 5 ng/ml of LIF was 43 %.
Statistically significant higher average fraction of contrac-
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Figure 2. AChR clustering in control and LIF treated 15 days old
co-cultures. Histograms present an average number of AChR clus-
ters per microscope field (400x) examined in the area of innerva-
tion. Number of fields examined in type of co-cultures is indicated
above bars. Asterisks denote significant differences from the con-
trol (P<0.05; t-test).
Figure 3. Number fraction of contraction-positive explants expres-
sed in percents during the time course of experiment in control
and LIF treated co-cultures. Number of spinal cord explants fol-
lowed in each set of co-cultures is indicated above bars. Explant
was considered contraction-positive if at least one contraction unit
had been detected in the area of innervation. Contraction unit was
defined as distinct group of muscle tubes contracting simultaneous-
ly at frequency, which was unique for this contracting unit and dif-
ferent from the contraction frequencies of other units. Asterisks de-
note significant differences from the control (P<0.05; t-test).
Figure 1. Neuronal outgrowth in control and LIF treated co-cultures
at different time points after establishment of co-cultures. Asterisks
denote significant differences from the control (P<0.05; t-test).
tion-positive explants in co-cultures treated with 10 ng/ml
(47 %), 20 ng/ml (52 %) and 50 ng/ml of LIF (53 %) in
comparison with control and co-cultures treated with
lower concentration of LIF was observed.
Efficiency of innervation was further determinated by
counting the number of contraction units per contrac-
tion-positive explant. In all co-cultures an increasing
number of contraction units per spinal cord explant could
be observed from day 7, when the first contraction was
observed. The average number of contracting units in all
co-cultures at the beginning of contraction was 2.05 ± 0.46
till day 17 after establishment of co-cultures (Figure 4).
Later on, no increase could be observed, however the
number of contracting units stayed at the same level
with 3.86 ± 0.23 in control co-cultures, 3.33 ± 0.58 in
co-cultures treated with 10 ng/ml and 3.65 ± 0.47 con-
tracting units in co-cultures treated with 10 ng/ml of LIF.
In co-cultures treated with 1 ng/ml of LIF the number of
contraction units never reached the number observed in
control co-cultures and was even statistically significant-
ly lower at later time points. We observed a significantly
higher number of contracting units firstly at day 14 after
establishment in co-cultures treated with 20 ng/ml of LIF
than in control co-cultures. This number stayed at the
higher level after that time point. Significantly, a higher
number than in the control co-culture was also observed
in co-cultures treated with 50 ng/ml of LIF, but firstly at
day 17 after establishment.
DISCUSSION
In the study presented here the effects of LIF on the for-
mation of NMJ in in vitro model of innervated human
muscle was studied. The experimental model employed
is so far the only model where early events in synapto-
genesis of NMJ could be followed and functional inner-
vation could be easily quantitated.20 The effects of LIF
on the formation of NMJ have not yet been systemati-
cally studied. We found, that certain concentrations of LIF
promote processes in NMJ formation like neuronal out-
growth, AChR accumulation and functional innervation.
These processes are important for successful NMJ for-
mation. We decided to follow these parameters since they
reflected on both neuronal and muscle development. Our
results are consistent with previous studies of neurotro-
phic and myotrophic effects of LIF.
We found, an increased neuronal outgrowth in co-
cultures treated with higher concentration of LIF but not
in co-cultures treated with lower LIF concentrations. This
result is consistent with study of Martinou et al.23 where
LIF supported motor neurons survival and increased
cholinacetyltransferase activity in cultures of isolated rat
embryonic motor neurons. LIF is the neurotrophic factor
known to have a wide range of effects that promote neu-
ronal outgrowth also in other nerve cell types.24 Positive
effects at higher concentrations could be explained by
cell complexity found in our experimental model.19
Complex interaction among neuronal and glial cell in
our experimental model may influence LIF effects or it
could be even mediated through Schwann cell25,26 or via
activation of mature astrocytes like it is in the case of
CNTF.27,28 White et al.29 reported that beneficial effects
of LIF at least on skeletal muscle development are medi-
ated by modulation of the extracellular matrix. This kind
of interaction requires higher concentration of LIF.30 An
increased neuronal outgrowth is also in accordance with
findings that LIF rescues motor neurons from axoto-
my.31,32 Motor neurons enter into the process of regener-
ation after nerve lesion, regeneration is successful only
if proper trophic stimuli are supplied. Typical reaction to
nerve lesion is an up-regulation of trophic factor recep-
tors mRNAs like LIFR.9,11 The regeneration process could
be compared to the first stages of innervation, where
motor neurons survival is dependent on proper target
trophic survival stimulation. Survival of motor neurons
is beside exogenously derivered LIF dependent also from
endogenously synthesized LIF, which increases after
nerve injury and where newly synthesized LIF is active-
ly transported in retro- and anterograde way.10,12,14
No direct studies of LIF on NMJ, to the best of our
knowledge, have yet to be performed. AChR clusters
counted in our experiments are equivalent to NMJs dur-
ing human muscle innervation. AChR cluster counting
was performed at the stage when most of NMJ are al-
ready formed. However, at this stage we could not dis-
tinguish between functional and non functional NMJ.
Higher concentrations of LIF caused an increase in num-
ber of AChR clusters. It was showed by Kwon et al.33
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Figure 4. The number of contracting units per contraction-positive
spinal cord explant at different time in co-cultures. Means ± S.D.
was determined for individual contraction positive explants of con-
trol and LIF treated co-cultures. Asterisks denote significant dif-
ferences from the control (P<0.05; t-test).
that LIF delays programmed withdrawal of newly form-
ed synapses from muscle, these findings could partially
explain increased number of AChR clusters in LIF treat-
ed co-cultures.
The higher average fraction of contraction-positive
explants and increased number of contraction units in
co-cultures treated with higher LIF concentrations is in
agreement with several studies of LIF myotrophic ef-
fects.13,34,35 Higher neuronal outgrowth means a greater
possibility for nerve-muscle contacts to be formed, which
in turn, results in a higher number of AChR clusters. Al-
though AChR clustering is a function of muscle cells it
is on the other hand strongly influenced by nerve derived
factors.2 This ability is exclusive function of cholinergic
neurons. It was shown that LIF in immature neurons ac-
tively governs a switch from an adrenergic to a cho-
linergic phenotype.36 Increased cholinergic activity how-
ever may influence the functional innervation of myo-
tubes. In skeletal muscle development LIF importantly
influence myoblast proliferation.13,37 Firstly, successful
myoblast proliferation and subsequent myotubes forma-
tion and survival are prerequisites for efficient innerva-
tion. Secondly, LIF promotes and is essential for muscle
regeneration after denervation38 or injury.16,35,39 In this way
LIF promotes not only muscle cell survival but also indi-
rectly stimulates reinnervation or even new innervation
of muscle. Lower degrees of successful innervation in
co-cultures treated with a lower concentration of LIF
could be explained either by the fact that neurotrophic
factors trigger positive effects only in specific narrow
concentration range40 or by negative interactions of LIF
with other endogenously secreted trophic factors. This
peculiar mechanism has to be taken in account for possi-
ble therapeutic use of neurotrophic factors.
In summary, our results show that in our experimen-
tal model only specific concentrations of LIF positively
promotes several processes important for NMJ forma-
tion and successful innervation which finally results in
the appearance of contracting myotubes. This study could
be an important contribution to the possible use of this
in vitro model of innervated human muscle in studying
other trophic substances on the formation and mainten-
ance of NMJ and to possible use of LIF as therapeutic
agent.
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SA@ETAK
U~inak LIF-a na stvaranje neuromuskularne spojnice u ko-kulturama eksplantata
le|ne mo`dine {takora i mi{i}a ~ovjeka
Toma` Mar{
Leukemijski inhibicijski ~imbenik (engl. Leukemia Inhibitory Factor, LIF) multifunkcionalni je citokin,
va`an za razvoj i odr`avanje `iv~anih i mi{i}nih stanica. U~inci LIF-a na stvaranje neuromuskularne spojnice
jo{ nisu sustavno istra`ivani. U ovom radu kori{ten je in vitro model kulture ljudskih mi{i}nih stanica inervi-
ranih embrionalnim motori~kim neuronima {takora, {to je omogu}ilo istra`ivanje razli~itih aspekata neuromus-
kularne spojnice. Cilj ovog istra`ivanja bio je ispitati poti~e li LIF razvoj funkcionalne neuromuskularne veze.
Ispitivani su u~inci LIF-a na rast neurona, akumulaciju acetilkolinskih receptora te nastanak funkcionalnih neu-
romuskularnih spojnica. Ko-kulture podra`ene ve}im koncentracijama LIF-a pokazale su pove}an rast neurona,
pove}an broj nakupina acetilkolinskih receptora, te u kasnijem periodu, nastanak ve}eg broja funkcionalnih
sinapsi. LIF u to~no odre|enom rasponu koncentracija promovira nastanak neuromuskularnih spojnica. U na-
{im ko-kulturama u~inci su bili izra`eniji u kasnijim stadijima formiranja neuromuskularnih veza. Opisani model
in vitro nastanka inerviranih ljudskih mi{i}nih stanica mo`e biti u~inkovit eksperimentalni sustav za testiranje
toksi~nih i terapeutskih u~inaka razli~itih tvari tijekom nastanka i razvoja neuromi{i}nih veza na stani~noj razini.
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